Trends over 5 years in cardiovascular medicine use in Australian veterans with diabetes

British Journal of Clinical Pharmacology

Volumn 64, Issue 1, 2007, Pages 100-104

  Roughead, Elizabeth E ^a   Pratt, Nicole ^b   Gilbert, Andrew L ^a  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

ACE inhibitors; Antiplatelet; Cardiovascular; Diabetes; Drug utilisation; Lipid lowering therapy

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; CARDIOVASCULAR AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; WARFARIN;

AGED; ARTICLE; AUSTRALIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIABETES MELLITUS; DRUG INDICATION; DRUG UTILIZATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; POPULATION RESEARCH; PRIORITY JOURNAL; VETERAN;

AGED; AGED, 80 AND OVER; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTILIPEMIC AGENTS; AUSTRALIA; CARDIOVASCULAR AGENTS; DIABETIC ANGIOPATHIES; FEMALE; HUMANS; MALE; PHYSICIAN'S PRACTICE PATTERNS; PLATELET AGGREGATION INHIBITORS; VETERANS;

EID: 34250656039     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2007.02853.x     Document Type: Article

References (17)

1. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003 348 : 383 93.
2. Australian Medicines Handbook Pty Ltd. Australian Medicines Handbook. Adelaide : Australian Medicines Handbook Pty Ltd 2005. Available at http://www.amh.net.au/ (last accessed: 17 January 2007).
3. Therapeutic Guidelines Ltd. e-TG complete. In : North Melbourne: Therapeutic Guidelines Ltd, 2006. Available at http://www.tg.com.au/ (last accessed: 17 January 2007).
4. Kemp TM, Barr EL, Zimmet PZ, Cameron AJ, Welborn TA, Colagiuri S, Phillips P, Shaw JE. Glucose, lipid, and blood pressure control in Australian adults with type 2 diabetes: the 1999-2000 AusDiab. Diabetes Care 2005 28 : 1490 2.
5. Colhoun HM, Dong W, Barakat MT, Mather HM, Poulter NR. The scope for cardiovascular disease risk factor intervention among people with diabetes mellitus in England: a population-based analysis from the Health Surveys for England 1991-94. Diabet Med 1999 16 : 35 40.
6. Supina AL, Guirguis LM, Majumdar SR, Lewanczuk RZ, Lee TK, Toth EL, Johnson JA. Treatment gaps for hypertension management in rural Canadian patients with type 2 diabetes mellitus. Clin Ther 2004 26 : 598 606.
7. Klinke JA, Johnson JA, Guirguis LM, Toth EL, Lee TK, Lewanczuk RZ, Majumdar SR. Underuse of aspirin in type 2 diabetes mellitus: prevalence and correlates of therapy in rural Canada. Clin Ther 2004 26 : 439 46.
8. Safford M, Eaton L, Hawley G, Brimacombe M, Rajan M, Li H, Pogach L. Disparities in use of lipid-lowering medications among people with type 2 diabetes mellitus. Arch Intern Med 2003 163 : 922 8.
9. Rosen AB. Indications for and utilization of ACE inhibitors in older individuals with diabetes. Findings from the National Health and Nutrition Examination Survey 1999-2002. J Gen Intern Med 2006 21 : 315 9.
10. World Health Organization Collaborating Centre for Drug Statistics Methodology. Anatomical Therapeutic Chemical Code Classification index with Defined Daily Doses. Oslo : WHO 2004. Available at http://www.whocc.no/atcddd/ (last accessed: 5 October 2006).
11. National Prescribing Service. Evaluation Report no. 8. Progress, Achievements and Future Directions. Surry Hills, NSW : National Prescribing Service 2005. Available at http://www.nps.org.au/resources/evaluation/report_08. pdf (last accessed: 5 October 2006).
12. Department of Veterans' Affairs. Veterans' MATES. Canberra : Department of Veterans Affairs 2006. Available at http://www.dva.gov.au/health/ veteransmates/index.htm (last accessed: 5 October 2006).
13. Australian Centre for Diabetes Strategies. National Evidence Based Guidelines for the Management of Type 2 Diabetes Mellitus. Canberra : National Health and Medical Research Council 2004. Available at http://www. diabetesaustralia.com.au/education_info/nebg.html (last accessed: 5 October 2006).
14. Australian Government Department of Health and Ageing. Health Priorities. Canberra : Australian Government Department of Health and Ageing 2006. Available at http://www.health.gov.au/internet/wcms/publishing.nsf/Content/ Health+Priorities-1 (last accessed: 5 October 2006).
15. Medicare Australia. Medicare Benefits Schedule (MBS) Item Statistics Reports. Australian Government Medicare Australia 2006, Canberra. Available at http://www.medicareaustralia.gov.au/providers/health_statistics/ statistical_reporting/medicare.htm (last accessed: 5 October 2006).
16. Dunstan D, Zimmet P, Welborn T, Sicree R, Armstrong T, Atkins R, Cameron A, Shaw J, Chadban S. Diabesity and Associated Disorders in Australia 2000. Melbourne : International Diabetes Institute 2001.
17. Donnelly N, McManus P, Dudley J, Hall W. Impact of increasing the re-supply interval on the seasonality of subsidised prescription use in Australia. Aust NZ J Public Health 2000 24 : 603 6.